INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39301, 26817, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39302, 27487, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39303, 27488, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39304, 27489, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39305, 27952, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39306, 31976, 'Cilostazol', 'Hemorrhage', 'Cilostazol inhibits platelet aggregation in a reversible manner.  Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding.  Avoid use of cilostazol tablets in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39307, 2707, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39308, 2710, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39309, 6465, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39310, 16329, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39311, 16330, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39312, 16331, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39313, 16332, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39314, 16451, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39315, 16453, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39316, 16455, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39317, 16581, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39318, 16583, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39319, 20796, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39320, 23018, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39321, 25010, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39322, 25011, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39323, 26692, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39324, 26693, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39325, 26816, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39326, 26817, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39327, 27487, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39328, 27488, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39329, 27489, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39330, 27952, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39331, 31976, 'Cilostazol', 'Heart Failure', 'The use of cilostazol is contraindicated in patients with heart failure of any severity.  Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III.  Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III- IV heart failure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39332, 2707, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39333, 2710, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39334, 6465, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39335, 16329, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39336, 16330, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39337, 16331, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39338, 16332, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39339, 16451, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39340, 16453, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39341, 16455, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39342, 16581, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39343, 16583, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39344, 20796, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39345, 23018, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39346, 25010, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39347, 25011, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39348, 26692, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39349, 26693, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39350, 26816, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39351, 26817, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39352, 27487, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39353, 27488, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39354, 27489, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39355, 27952, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39356, 31976, 'Cilostazol', 'Hepatic Insufficiency', 'No cilostazol dose adjustment is required in patients with mild hepatic impairment.  Patients with moderate or severe hepatic impairment have not been studied in clinical trials and dosing recommendations cannot be provided.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39357, 2707, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39358, 2710, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39359, 6465, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39360, 16329, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39361, 16330, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39362, 16331, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39363, 16332, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39364, 16451, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39365, 16453, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39366, 16455, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39367, 16581, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39368, 16583, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39369, 20796, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39370, 23018, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39371, 25010, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39372, 25011, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39373, 26692, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39374, 26693, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39375, 26816, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39376, 26817, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39377, 27487, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39378, 27488, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39379, 27489, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39380, 27952, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39381, 31976, 'Cilostazol', 'Myocardial Ischemia', 'Cilostazol may induce tachycardia, palpitation, tachyarrhythmia or hypotension.  The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm.  Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39382, 0, 'Chorionic Gonadotropin (Human)', 'Prostatic Neoplasms', 'The use of chorionic gonadotropin is contraindicated for use in patients with prostatic or other androgen- dependent neoplasm.  HCG activity is identical to that of luteinizing hormone (LH) and, to a small degree, that of follicle-stimulating hormone (FSH), resulting in production of androgens by the testis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39383, 0, 'Chorionic Gonadotropin (Human)', 'Edema', 'Chorionic gonadotropin (HCG) induction of androgen secretion can result in fluid retention.  Therapy with chorionic gonadotropin (HCG) should be administered cautiously in patients adversely affected by sodium and water retention such as patients with cardiac or renal disease, epilepsy, migraine or asthma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39384, 13865, 'Ciclesonide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39385, 13867, 'Ciclesonide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39386, 28040, 'Ciclesonide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39387, 28041, 'Ciclesonide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39388, 28042, 'Ciclesonide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39389, 13865, 'Ciclesonide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39390, 13867, 'Ciclesonide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39391, 28040, 'Ciclesonide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39392, 28041, 'Ciclesonide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39393, 28042, 'Ciclesonide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39394, 13865, 'Ciclesonide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39395, 13867, 'Ciclesonide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39396, 28040, 'Ciclesonide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39397, 28041, 'Ciclesonide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39398, 28042, 'Ciclesonide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39399, 13865, 'Ciclesonide', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (39400, 13867, 'Ciclesonide', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', '', 'DDInter', 0);
